"The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved t"...
Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC).
Proleukin is indicated for the treatment of adults with metastatic melanoma.
Careful patient selection is mandatory prior to the administration of Proleukin. See “CONTRAINDICATIONS”, “WARNINGS” and “PRECAUTIONS” sections regarding patient screening, including recommended cardiac and pulmonary function tests and laboratory tests.
Evaluation of clinical studies to date reveals that patients with more favorable ECOG performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a higher response rate and lower toxicity (See “CLINICAL PHARMACOLOGY” section, “Clinical Studies” section and “ADVERSE REACTIONS” section). Therefore, selection of patients for treatment should include assessment of performance status.
Experience in patients with ECOG PS > 1 is extremely limited.
DOSAGE AND ADMINISTRATION
The recommended Proleukin® (aldesleukin) treatment regimen is administered by a 15 minute intravenous infusion every 8 hours. Before initiating treatment, carefully review the “INDICATIONS AND USAGE”, “CONTRAINDICATIONS”, “WARNINGS”, “PRECAUTIONS”, and “ADVERSE REACTIONS” sections, particularly regarding patient selection, possible serious adverse events, patient monitoring and withholding dosage. The following schedule has been used to treat adult patients with metastatic renal cell carcinoma (metastatic RCC) or metastatic melanoma. Each course of treatment consists of two 5-day treatment cycles separated by a rest period.
600,000 International Units/kg (0.037 mg/kg) dose administered every 8 hours by a 15-minute intravenous infusion for a maximum of 14 doses. Following 9 days of rest, the schedule is repeated for another 14 doses, for a maximum of 28 doses per course, as tolerated. During clinical trials, doses were frequently withheld for toxicity (See “Clinical Studies” section and “Dose Modifications” subsection). Metastatic RCC patients treated with this schedule received a median of 20 of the 28 doses during the first course of therapy. Metastatic melanoma patients received a median of 18 doses during the first course of therapy.
Patients should be evaluated for response approximately 4 weeks after completion of a course of therapy and again immediately prior to the scheduled start of the next treatment course. Additional courses of treatment should be given to patients only if there is some tumor shrinkage following the last course and retreatment is not contraindicated (See “CONTRAINDICATIONS” section). Each treatment course should be separated by a rest period of at least 7 weeks from the date of hospital discharge.
Dose modification for toxicity should be accomplished by withholding or interrupting a dose rather than reducing the dose to be given. Decisions to stop, hold, or restart Proleukin therapy must be made after a global assessment of the patient. With this in mind, the following guidelines should be used:
Retreatment with Proleukin
is contraindicated in patients who have experienced the following toxicities:
|Cardiovascular||Sustained ventricular tachycardia ( ≥ 5 beats)|
|Cardiac rhythm disturbances not controlled or unresponsive to management|
|Chest pain with ECG changes, consistent with angina or myocardial infarction|
|Respiratory||Intubation for > 72 hours|
|Urogenital||Renal failure requiring dialysis > 72 hours|
|Nervous||Coma or toxic psychosis lasting > 48 hours|
|Repetitive or difficult to control seizures|
|GI bleeding requiring surgery|
Doses should be held and restarted according to the following:
|Body System||Hold dose for||Subsequent doses may be given if|
|Cardiovascular||Atrial fibrillation, supraventricular tachycardia or bradycardia that requires treatment or is recurrent or persistent||Patient is asymptomatic with full recovery to normal sinus rhythm|
|Systolic bp < 90 mm Hg with increasing requirements for pressors||Systolic bp ≥ 90 mm Hg and stable or improving requirements for pressors|
|Any ECG change consistent with MI, ischemia or myocarditis with or without chest pain; suspicion of cardiac ischemia||Patient is asymptomatic, MI and myocarditis have been ruled out, clinical suspicion of angina is low; there is no evidence of ventricular hypokinesia|
|Respiratory||O2 saturation < 90%||O2 saturation > 90%|
|Nervous||Mental status changes, including moderate confusion or agitation||Mental status changes completely resolved|
|Body as a Whole||Sepsis syndrome, patient is clinically unstable||Sepsis syndrome has resolved, patient is clinically stable, infection is under treatment|
|Urogenital||Serum creatinine > 4.5 mg/dL or a serum creatinine of ≥ 4 mg/dL in the presence of severe volume overload, acidosis, or hyperkalemia||Serum creatinine < 4 mg/dL and fluid and electrolyte status is stable|
|Persistent oliguria, urine output of < 10 mL/hour for 16 to 24 hours with rising serum creatinine||Urine output > 10 mL/hour with a decrease of serum creatinine > 1.5 mg/dL or normalization of serum creatinine|
|Digestive||Signs of hepatic failure including encephalopathy, increasing ascites, liver pain, hypoglycemia||All signs of hepatic failure have resolved*|
|Stool guaiac repeatedly > 3-4+||Stool guaiac negative|
|Skin||Bullous dermatitis or marked worsening of pre-existing skin condition, avoid topical steroid therapy||Resolution of all signs of bullous dermatitis|
|* Discontinue all further treatment for that course. A new course of treatment, if warranted, should be initiated no sooner than 7 weeks after cessation of adverse event and hospital discharge.|
Reconstitution and Dilution Directions: Reconstitution and dilution procedures other than those recommended may alter the delivery and/or pharmacology of Proleukin and thus should be avoided.
- Proleukin® (aldesleukin) is a sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution. EACH VIAL CONTAINS 22 MILLION International Units (1.3 mg) OF PROLEUKIN AND SHOULD BE RECONSTITUTED ASEPTICALLY WITH 1.2 mL OF STERILE WATER FOR INJECTION, USP. WHEN RECONSTITUTED AS DIRECTED, EACH mL CONTAINS 18 MILLION International Units (1.1 mg) OF PROLEUKIN. The resulting solution should be a clear, colorless to slightly yellow liquid. The vial is for single-use only and any unused portion should be discarded.
- During reconstitution, the Sterile Water for Injection, USP should be directed at the side of the vial and the contents gently swirled to avoid excess foaming. DO NOT SHAKE.
- The dose of Proleukin,
reconstituted with Sterile Water for Injection, USP (without preservative)
should be diluted aseptically in 50 mL of 5% Dextrose Injection, USP (D5W) and
infused over a 15-minute period.
In cases where the total dose of Proleukin is 1.5 mg or less (e.g., a patient with a body weight of less than 40 kilograms), the dose of Proleukin should be diluted in a smaller volume of D5W. Concentrations of Proleukin below 0.03 mg/mL and above 0.07 mg/mL have shown increased variability in drug delivery. Dilution and delivery of Proleukin outside of this concentration range should be avoided.
- Glass bottles and plastic (polyvinyl chloride) bags have been used in clinical trials with comparable results. It is recommended that plastic bags be used as the dilution container since experimental studies suggest that use of plastic containers results in more consistent drug delivery. In-line filters should not be used when administering Proleukin.
- Before and after reconstitution and dilution, store in a refrigerator at 2° to 8°C (36° to 46°F). Do not freeze. Administer Proleukin within 48 hours of reconstitution. The solution should be brought to room temperature prior to infusion in the patient.
- Reconstitution or dilution with Bacteriostatic Water for Injection, USP, or 0.9% Sodium Chloride Injection, USP should be avoided because of increased aggregation. Proleukin should not be coadministered with other drugs in the same container.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Proleukin® (aldesleukin) is supplied in individually boxed single-use vials. Each vial contains 22 million International Units of Proleukin. Discard unused portion.
NDC 65483-116-07 Individually boxed single-use vial
Store vials of lyophilized Proleukin in a refrigerator at 2° to 8°C (36° to 46°F). PROTECT FROM LIGHT. Store in carton until time of use.
Reconstituted or diluted Proleukin is stable for up to 48 hours at refrigerated and room temperatures, 2° to 25°C (36° to 77°F). However, since this product contains no preservative, the reconstituted and diluted solutions should be stored in the refrigerator.
Do not use beyond the expiration date printed on the vial. NOTE: This product contains no preservative.
Manufactured by: Prometheus Laboratories Inc. San Diego, CA 92121. At Bayer HealthCare Pharmaceuticals Emeryville, CA 94608. REV: July 2012This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/13/2016
Additional Proleukin Information
Proleukin - User Reviews
Proleukin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.